‘Suglat’ landed in large hospitals after ‘Forxiga’
It was observed ‘Suglat,’ a SGLT-2 inhibitor recognize as a new diabetes drug, has been settled in large hospitals, followed by the same type drug, ‘Forxiga.’
According to the observation of Medipana News on the 6th, ‘Suglat(generic name: ipragliflozin, Astellas Pharma)’ which acquired the healt...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
